Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
14
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic

      letter
      , PharmD, , MD
      Infection Control and Hospital Epidemiology
      Cambridge University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor—The coronavirus disease 2019 (COVID-19) pandemic has adversely impacted nearly all aspects of life since emerging in late 2019. Notably, surges in COVID-19 cases have led to antibiotic overprescribing in the inpatient setting, hampering ongoing antimicrobial stewardship efforts. 1,2 However, patients’ reluctance to seek healthcare during the pandemic, particularly for minor ailments, may lead to unexpected outpatient antimicrobial stewardship gains. Jeffery et al 3 reported an inverse relationship between COVID-19 cases and daily counts of emergency department visits in 5 US states between January and April of 2020. Diagnoses were not reported in this study, and the authors concluded that clinicians should reinforce to patients the importance of seeking emergency department care for serious conditions. We have previously reported the results of a systemwide initiative to reduce antibiotic prescribing for ambulatory adults with acute, uncomplicated bronchitis. 4 Internally, we continue to track and report these data. Recently, we observed a profound reduction in both the overall number of patients seen and discharged with a primary diagnosis of bronchitis and the number of antibiotic prescriptions written for these encounters (Fig. 1). In addition to patients’ not seeking care due to the pandemic, there are a number of other, possible explanations for our observed decline in visits. Stay-at-home orders and social distancing appear to have reduced the burden of common respiratory viruses in the community, leading to fewer cases of acute, uncomplicated bronchitis, 5,6 for which the primary etiology is viral. 7 Patients may increasingly seek care outside of our health system during the pandemic. The pandemic has also shifted patient care to telemedicine. To assess this phenomenon, we captured whether or not a visit was a telemedicine encounter and then analyzed the recent ambulatory clinic data. Of the 394 ambulatory clinic bronchitis visits during July and August, 112 (28.4%) were telemedicine encounters, a higher proportion of total visits than observed in previous months. Thus, a shift toward more telemedicine visits was revealed in our data set. Fig. 1. Number of ambulatory patients with a primary diagnosis of bronchitis, April 2017–August 2020. Complete lines, number of visits; dashed lines, number of antibiotic prescriptions. The COVID-19 pandemic, while challenging for so many other aspects of antimicrobial stewardship, has led to an overall net reduction in ambulatory adults seeking care for bronchitis in our health system and to a dramatic reduction in antibiotic prescribing for that condition. Reducing unnecessary, outpatient antibiotic prescribing has long been a difficult challenge for many antimicrobial stewardship programs. Our challenge will be to educate patients and clinicians to maintain these improvements in outpatient, acute bronchitis management as the pandemic is brought under control and outpatient visits return to prepandemic levels.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Trends in Emergency Department Visits and Hospital Admissions in Health Care Systems in 5 States in the First Months of the COVID-19 Pandemic in the US

          This cross-sectional study examines trends in emergency department visits and visits that led to hospitalizations during a 4-month period leading up to and during the COVID-19 outbreak in the US.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Social Distancing for COVID-19 and Diagnoses of Other Infectious Diseases in Children

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern

              To the Editor—The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a public health problem of historic dimensions. However, this pandemic is occurring in the setting of an antimicrobial resistance crisis that is increasing at an alarming pace worldwide. Of concern, countries with a particularly high incidence of COVID-19 also have significant rates of infection caused by multidrug-resistant bacteria. During the 2009 influenza pandemic, coinfection with bacteria was identified as a prognostic factor for the worse outcomes. 1 This finding has led to empirical antibiotic therapy being recommended for patients with suspected influenza pneumonia, 2 and it has probably been a major reason underpinning the initial World Health Organization’s recommendation to use empirical antibiotics in cases of COVID-19 pneumonia. 3 Although this guideline advocated for early antimicrobial de-escalation, a couple of factors may have hindered this practice. First, processing microbiological samples in saturated emergency rooms and overloaded laboratories is difficult. Second, no evidence-based antiviral treatment for COVID-19 has been developed in the setting of a highly stressful situation. Together, these factors may have prompted clinicians to prescribe broad-spectrum antimicrobials more often than they may otherwise have. Therefore, antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. 4 To date, however, no study has evaluated the impact of the COVID-19 pandemic on antibiotic consumption. We conducted a before-and-after cross-sectional study comparing data in 2019 (before the COVID-19 pandemic began) and 2020 (COVID-19) for the periods from January 1 to April 30. Bellvitge University Hospital is a 700-bed hospital that serves as a public referral center of 1 million inhabitants in Catalonia, the second worst pandemic-affected area in Spain. 5 As of April 30, 2020, this hospital had had >1,293 hospital admissions for COVID-19, with a 317% increase in critical care bed use. In this study, we calculated the defined daily dose per 100 patient days, as described elsewhere, and based on the dispensing data of our electronic prescribing system. Medians for continuous variables were compared using the Wilcoxon log-rank test. Antibiotic use was similar in January and February of both 2019 and 2020, with a slightly lower consumption in 2020 (Fig. 1). As expected, as the COVID-19 pandemic dramatically progressed through March and April 2020, the overall monthly antibiotic usage increased significantly compared with 2019 (P < .001). Interestingly, we observed a biphasic phenomenon. During the first peak in March 2020, amoxicillin/clavulanate use trended upward rapidly, consistent with hospital recommendations regarding empirical antibiotic treatment in patients with COVID-19. During the second peak in April 2020, however, we observed a significant increase in broad-spectrum antibiotic prescribing and a slight decrease in amoxicillin/clavulanate use. The biphasic pattern of antibiotic use was associated with 2 specific moments of the pandemic. The first moment corresponded to the empirical coverage of all cases of COVID-19 pneumonia and a high admission rate to our hospital (1,269 patients between March 12 and April 12). The second moment corresponded to a phase in which admission to critical care units accumulated for patients with more severe disease, probably corresponding with an increase in nosocomial infection. Fig. 1. Total antimicrobial consumption and comparative consumption of a amoxicillin/clavulanate and broad-spectrum antibiotics during the first 4 months of 2019 and 2020. Broad-spectrum antibiotics included cefepime, piperacillin/tazobactam, meropenem, imipenem, and ertapenem. Note. DDD, defined daily dose. Despite the lack of formal recommendation for the inclusion of antimicrobial stewardship programs in emergency response preparedness efforts, it has been suggested that these programs are essential to mitigate the damage caused by the pandemic. 6 The initial uncertainty and the difficulty in obtaining microbiological results have been determining factors in the difficulty of implementing an antimicrobial stewardship approach during the COVID-19 pandemic. This lack of information can be explained by several factors: insufficient follow-up times, the heterogeneous use of immunomodulatory drugs, and differences in the availability of infection control measures based on the number of cases per center. 7 As has been recently shown, bacterial coinfection in COVID-19 appears to be scarce (2.1%). 8 Notably, superinfection in critically ill patients might be higher (13.5%), and up to 94% of critically ill patients are treated with antibiotics. 9 Nevertheless, we are not aware of studies that have specifically investigated the development of superinfection by antimicrobial-resistant microorganisms in COVID-19 patients. In this scenario, we think that standardizing immunomodulatory treatments, ensuring compliance with usual infection control practices, and carefully interpreting microbiological results will be key measures that could favor a more cautious approach to the use of antibiotics. We identified a biphasic pattern of increased antibiotic use that corresponded with a first wave of empirical antibiotic therapy and a second biphasic pattern with higher use of broad-spectrum antibiotics. To the best of our knowledge, this is the first description of antibiotic use dynamics during the COVID-19 pandemic. However, this study has some limitations. First, we did not provide information about the clinical indications for the antibiotic use. Second, as a single-center study, local factors that preclude the extrapolation of our findings to other centers. In conclusion, our data support the World Health Organization concern regarding inappropriate use of antibiotics during the pandemic and the recent change in its guidelines discouraging empirical antibiotics in COVID-19. 10 Long-term studies are needed to assess the impact of the increase in antibiotic use during COVID-19 pandemic on the hospital flora, and in turn, how this might affect future nosocomial infection and antimicrobial resistance trends worldwide. Meanwhile, it is crucial to standardize the use of antimicrobial stewardship principles to provide the safest therapeutic strategy not only for our present patients but also our future patients.
                Bookmark

                Author and article information

                Journal
                Infect Control Hosp Epidemiol
                Infect Control Hosp Epidemiol
                ICE
                Infection Control and Hospital Epidemiology
                Cambridge University Press (New York, USA )
                0899-823X
                1559-6834
                28 September 2020
                : 1-2
                Affiliations
                AdvocateAuroraHealth , Milwaukee, Wisconsin
                Author notes
                Author for correspondence: Thomas J. Dilworth, E-mail: thomas.dilworth@ 123456aah.org
                Author information
                https://orcid.org/0000-0002-7894-586X
                Article
                S0899823X20012337
                10.1017/ice.2020.1233
                7542319
                32985397
                6b123442-bf1d-48f3-8ca3-ec19048051e8
                © The Society for Healthcare Epidemiology of America 2020

                This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 16 September 2020
                : 19 September 2020
                Page count
                Figures: 1, References: 7, Pages: 2
                Categories
                Letter to the Editor

                Comments

                Comment on this article